Trials / Completed
CompletedNCT03083990
Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male
Compare IBI305 to Avastin on the Pharmacokinetics, Safety, Tolerance and Immunogenicity of a Single Dose In Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI305(Bevacizumab Biosimilar) | 3mg/kg, infusion in 90minutes |
| DRUG | Avastin(Bevacizumab) | 3mg/kg, infusion in 90minutes |
Timeline
- Start date
- 2017-03-09
- Primary completion
- 2017-08-17
- Completion
- 2017-08-17
- First posted
- 2017-03-20
- Last updated
- 2020-11-27
- Results posted
- 2020-11-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03083990. Inclusion in this directory is not an endorsement.